Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus to Screen Targets for CHDI

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioFocus will perform drug-candidate screening and related services for the CHDI Foundation's Huntington's disease drug development programs under a five-year collaboration agreement, BioFocus' parent company Galapagos said today.

BioFocus will be eligible for up to $41 million in research fees over the course of the collaboration, for which it will use its full range of integrated drug discovery services. These discovery efforts will include neuronal assay development, high-content screening, fragment-based screening, computational chemistry, protein crystallography, as well as studies involving pharmacokinetics, absorption, distribution, metabolism, and elimination.

This agreement continues and expands a collaboration between the UK-based company and the non-profit institution that started in 2005.

"We are confident that the next five years of this long-standing relationship with CHDI will be as productive as the first five," Galapagos CEO Onno van de Stolpe said in a statement.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.